The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Financing Update

8 Apr 2019 07:00

RNS Number : 3608V
Venn Life Sciences Holdings PLC
08 April 2019
 

8 April 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Financing Update

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces that Raglan Capital Limited, of whom Cathal Friel is a principal and owner, has subscribed for loan notes of £250,000 with a term of 13 months and a 8% coupon. The interest on the notes will be paid annually. The issue of the loan notes follows the previously announced financing of 11 December 2018 albeit on improved terms for the Company i.e. at a lower coupon and without any warrants or convertibility. The proceeds of the loan note will be applied to the Company's working capital.

Related Party Transaction

The subscription by Raglan Capital is considered a related party transaction for the purposes of Rule 13 of the AIM Rules for Companies. The Directors (other than Cathal Friel) consider, having consulted with Arden Partners, the Company's nominated adviser, that the terms of the subscription by Raglan Capital are fair and reasonable in so far as its Shareholders are concerned.

Enquiries:

Venn Life Sciences Holdings Plc Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners (Nominated Advisor and Joint Broker) Tel: +44 (0)20 7614 5900John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

About Venn Life Sciences

Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences www.vennlifesciences.com

Venn life Science: getintouch@vennlife.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDLFFLISFIDIIA
Date   Source Headline
29th Jan 20204:43 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSCompulsory Acquisition of Remaining hVIVO Shares
27th Jan 20203:00 pmRNSHolding(s) in Company
23rd Jan 20207:00 amRNSUpdate on Placing
22nd Jan 20209:58 amRNSHolding(s) in Company
22nd Jan 20209:48 amRNSHolding(s) in Company
21st Jan 20202:07 pmRNSHolding(s) in Company
20th Jan 20204:28 pmRNSHolding(s) in Company
20th Jan 20208:00 amRNSEuronext Growth Dublin Notice
20th Jan 20207:59 amRNSEuronext Growth Dublin Cancellation Notice
20th Jan 20207:00 amRNSCompletion of Merger with hVIVO and Re-Admission
17th Jan 20207:00 amRNSOffer Wholly Unconditional
16th Jan 20202:00 pmRNSSchedule One Update
16th Jan 20202:00 pmRNSSchedule One Update - Open Orphan PLC
15th Jan 20205:30 pmRNSOpen Orphan
14th Jan 202011:12 amGNWForm 8.3 - Open Orphan plc
14th Jan 20207:00 amRNSSecond Closing of the Offer
13th Jan 20209:00 amRNSPrice Monitoring Extension
7th Jan 20202:12 pmRNSPublication and Posting of Rule 15 Proposals
6th Jan 20201:17 pmRNSResult of General Meeting
6th Jan 20208:00 amRNSSchedule One - Open Orphan plc
6th Jan 20208:00 amRNSSchedule One
6th Jan 20207:00 amRNSNew 3 Year Contract
2nd Jan 202011:55 amRNSForm 8.5 (EPT/NON-RI)
2nd Jan 202011:44 amRNSForm 8.3 - Open Orphan PLC
31st Dec 201911:00 amRNSForm 8.5 (EPT/NON-RI)
31st Dec 20197:00 amRNSOffer Update
30th Dec 201910:00 amRNSForm 8.5 (EPT/NON-RI)
23rd Dec 201910:00 amRNSForm 8.5 (EPT/RI) - Open Orphan plc
23rd Dec 20199:30 amRNSForm 8.5 (EPT/NON-RI)
20th Dec 20195:39 pmRNSForm 8.3 - Open Orphan Plc
19th Dec 20194:39 pmRNSForm 8.3 - Open Orphan plc
19th Dec 20191:36 pmRNSForm 8.3 - Open Orphan plc
19th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
18th Dec 201912:05 pmRNSForm 8.5 (EPT/NON-RI)
18th Dec 20197:00 amRNSNew Contract with SFA Therapeutics
17th Dec 20194:38 pmRNSForm 8.3 - Open Orphan Plc
17th Dec 20194:36 pmRNSForm 8 (OPD)
17th Dec 20192:06 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:06 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:04 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 20192:04 pmRNSForm 8.3 - Open Orphan PLC
17th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
17th Dec 201910:19 amRNSForm 8 (OPD)
17th Dec 201910:19 amRNSForm 8 (OPD) (hVIVO plc)
16th Dec 20192:02 pmRNSForm 8 (OPD) Open Orphan plc
16th Dec 201911:55 amRNSForm 8.5 (EPT/NON-RI)
16th Dec 201910:26 amRNSForm 8.5 (EPT/RI) - Open Orphan plc
13th Dec 201911:44 amRNSForm 8.3 - Open Orphan PLC
13th Dec 20197:00 amRNSForm 8.3 - Open Orphan plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.